I’m seeking board-certified cardiologists, cardiovascular researchers, or pharmDs to comment on a recent study indicating that women treated with beta blockers after myocardial infarction have a higher risk of death, recurrent MI, or hospitalization for heart failure compared to men.
I’d like to hear from experts who can discuss:
Possible physiological or pharmacologic reasons for sex-based differences in beta blocker response
Whether this study challenges current post-MI management guidelines
How these findings could impact clinical decision-making for female patients